These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19830388)

  • 1. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
    Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
    Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
    Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
    J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
    Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients.
    Zlobec I; Molinari F; Martin V; Mazzucchelli L; Saletti P; Trezzi R; De Dosso S; Vlajnic T; Frattini M; Lugli A
    World J Gastroenterol; 2010 Oct; 16(38):4823-31. PubMed ID: 20939111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
    N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
    Muro K; Yoshino T; Doi T; Shirao K; Takiuchi H; Hamamoto Y; Watanabe H; Yang BB; Asahi D
    Jpn J Clin Oncol; 2009 May; 39(5):321-6. PubMed ID: 19287023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
    Maréchal R; De Schutter J; Nagy N; Demetter P; Lemmers A; Devière J; Salmon I; Tejpar S; Van Laethem JL
    BMC Cancer; 2010 Jun; 10():340. PubMed ID: 20591136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
    Pantelic A; Markovic M; Pavlovic M; Jancic S
    J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
    Frattini M; Saletti P; Romagnani E; Martin V; Molinari F; Ghisletta M; Camponovo A; Etienne LL; Cavalli F; Mazzucchelli L
    Br J Cancer; 2007 Oct; 97(8):1139-45. PubMed ID: 17940504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.